医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Solasia Initiates Phase 2 Study of Darinaparsin (SP-02) for Peripheral T-Cell Lymphoma

2016年03月28日 PM03:00
このエントリーをはてなブックマークに追加


 

TOKYO

Solasia Pharma K.K. (Headquarters: Tokyo, Japan, President: Yoshihiro Arai, hereinafter “Solasia”) announced today that an Asian Multinational Phase II study of SP-02 (darinaparsin) for injection (SP-02L) for the treatment of relapsed and refractory peripheral T-cell lymphoma (PTCL) has commenced. This single-arm, open-label, non-randomized study is being conducted in Japan, South Korea, Taiwan and Hong Kong; to evaluate the efficacy and safety of SP-02L monotherapy.

SP-02 is a novel mitochondrial-targeted agent being developed for the treatment of various hematologic and solid cancers. In a US Phase II study, SP-02 demonstrated clinical activity in lymphoma, in particular PTCL. In Phase I studies, in Japan and South Korea, safety and potential efficacy against PTCL have also been demonstrated. Based on the Phase II result, Solasia intends to file for registration in Japan, South Korea, Taiwan and Hong Kong.

Solasia obtained an exclusive worldwide license to develop and commercialize SP-02 from ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP), and the company is currently conducting clinical trials in Japan and other parts of Asia. Solasia granted development and commercialization rights of SP-02 in Japan to Meiji Seika Pharma Co. Ltd.

About Solasia:

Solasia was formed in November 2006 by MPM Capital and ITOCHU Corporation to address unmet needs for important new Western oncology therapies and supportive care products throughout Asia. The company’s mission is to expedite patient access to unique oncology therapies through aggressive development and specialized commercialization throughout Japan, China and other Asian countries. Solasia recently completed Series D financing of JPY2.08 billion in August 2015. The funds will be used to prepare for launch of Sancuso® and further advance clinical development of its existing pipeline. To date, Solasia has raised approximately $80 million in venture financing. Additional information is available at http://www.solasia.co.jp/en/

View source version on businesswire.com: http://www.businesswire.com/news/home/20160327005013/en/

CONTACT

Solasia Pharma K.K.
Koji Shinozaki, +81-3-6721-8330
Vice
President, Business Development
kshinozaki@solasia.co.jp
or
Annes
Associates
Shari Annes, +1-650-888-0902
sannes@annesassociates.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Shinkowa Pharmaceutical Co., Ltd., Distributor of the World’s First Supplements Containing β-Nicotinamide Mononucleotide (NMN), Has Begun World-Wide Distribution of the Special Products “NMN PURE 3000″ and “NMN PURE 1500″
  • Interim Analysis of Ignyta’s Entrectinib Suggests Potential Best-in-Class Profile as a First-Line Targeted Therapy in Patients With ROS1-Positive Non-Small Cell Lung Cancer
  • Spectrum Pharmaceuticals Highlights Poziotinib Data in Non-Small-Cell Lung Cancer (NSCLC) Presented at the 18th IASLC World Conference on Lung Cancer in Japan
  • 武田呈报ALUNBRIGTM (brigatinib)治疗ALK阳性非小细胞肺癌枢纽性2期ALTA试验的更新结果
  • GenePeeks Expands Distribution to India with Exclusive Agreement with CORE Diagnostics